Last reviewed 2026-04-22 · How we verify

AL0704rP

AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization.

AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization. Used for Allergic rhinitis and/or allergic asthma (specific allergen to be determined by trial design).

At a glance

Mechanism of action

As an investigational allergen product from Allergopharma, AL0704rP likely works by gradually inducing immune tolerance to target allergens, potentially through mechanisms involving regulatory T cell expansion and shift from Th2 to Th1/Treg responses. The exact formulation and delivery mechanism are proprietary, but allergen immunotherapies typically aim to reduce allergic symptoms and IgE-mediated responses while increasing blocking IgG antibodies.

Approved indications

• Allergic rhinitis and/or allergic asthma (specific allergen to be determined by trial design)

Common side effects

• Local injection site reactions (erythema, swelling, pruritus)
• Systemic allergic reactions
• Oral allergy syndrome (if sublingual formulation)

Key clinical trials

• Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AL0704rP CI brief — competitive landscape report
• AL0704rP updates RSS · CI watch RSS
• Allergopharma GmbH & Co. KG portfolio CI